• Archives:
    11articles
    Sort by
    Latest
    Open Access
    Review
    Nonalcoholic fatty liver disease and portal hypertension
    Nonalcoholic fatty liver disease (NAFLD) is a substantial and growing problem worldwide and has become the second most common indication for liver transplantation as it may progress to cirrhosis and...
    Marvin Ryou ... Gyorgy Baffy
    Published: June 29, 2020 Explor Med. 2020;1:149-169
    DOI: https://doi.org/10.37349/emed.2020.00011
    This article belongs to the special issue Exploring NAFLD/NASH
    Viewed:327
    Downloaded:8
    Cited:0
    Open Access
    Original Article
    Reduction of endoglin receptor impairs mononuclear cell-migration
    Aim: To test if the impairment of mononuclear cell (MNC) migration in patients with hereditary hemorrhagic telangiectasia (HHT) is due to the reduction of the endoglin (ENG) receptor on the cell su...
    Zhenying Han ... Hua Su
    Published: May 22, 2020 Explor Med. 2020;1:Online First
    DOI: https://doi.org/10.37349/emed.2020.00010
    Viewed:385
    Downloaded:11
    Cited:0
    Open Access
    Original Article
    Placental OPRM1 DNA methylation and associations with neonatal opioid withdrawal syndrome, a pilot study
    Aims: Epigenetic variation of DNA methylation of the mu-opioid receptor gene (OPRM1) has been identified in the blood and saliva of individuals with opioid use disorder (OUD) and infants with neona...
    Elisha M. Wachman ... Huiping Zhang
    Published: June 29, 2020 Explor Med. 2020;1:124-135
    DOI: https://doi.org/10.37349/emed.2020.00009
    This article belongs to the special issue The Biological Basis of Substance Use Disorders
    Viewed:287
    Downloaded:6
    Cited:0
    Open Access
    Meta-Analysis
    GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis
    Aim: Recent randomized controlled trials (RCTs) have tested the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) to specifically treat non-alcoholic fatty liver disease (NAFLD). We ...
    Alessandro Mantovani ... Giovanni Targher
    Published: June 29, 2020 Explor Med. 2020;1:108-123
    DOI: https://doi.org/10.37349/emed.2020.00008
    This article belongs to the special issue Exploring Type 2 Diabetes Mellitus
    Viewed:274
    Downloaded:6
    Cited:0
    Open Access
    Review
    Perspectives of nonalcoholic fatty liver disease research: a personal point of view
    Rational government of patient fluxes from primary care to hepatology clinic is a priority of nonalcoholic fatty liver disease (NAFLD) research. Estimating pre-test probability of disease, risk of f...
    Amedeo Lonardo, Stefano Ballestri
    Published: June 29, 2020 Explor Med. 2020;1:85-107
    DOI: https://doi.org/10.37349/emed.2020.00007
    This article belongs to the special issue Exploring NAFLD/NASH
    Viewed:435
    Downloaded:15
    Cited:0
    Open Access
    Review
    Understanding cardiac systolic performance beyond left ventricular ejection fraction
    Left ventricular ejection fraction is the critical parameter used for heart failure classification, decision making and assessing prognosis. It is defined as a volumetric ratio and is essentially a ...
    Elena-Laura Antohi, Ovidiu Chioncel
    Published: April 30, 2020 Explor Med. 2020;1:75-84
    DOI: https://doi.org/10.37349/emed.2020.00006
    Viewed:402
    Downloaded:6
    Cited:0
    Open Access
    Review
    Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease
    Non-alcoholic fatty liver disease (NAFLD) remains a major cause of chronic liver disease worldwide. Despite extensive studies, the heterogeneity of the risk factors as well as different disease mech...
    Noel C. Salvoza ... Natalia Rosso
    Published: April 30, 2020 Explor Med. 2020;1:51-74
    DOI: https://doi.org/10.37349/emed.2020.00005
    This article belongs to the special issue Exploring NAFLD/NASH
    Viewed:690
    Downloaded:16
    Cited:1
    Open Access
    Review
    PNPLA3 gene and kidney disease
    Chronic kidney disease (CKD) is a disease regularly seen in clinical practice. At present, CKD is described as a change of kidney structure and/or function and it is classified in relation to cause,...
    Alessandro Mantovani, Chiara Zusi
    Published: February 29, 2020 Explor Med. 2020;1:42-50
    DOI: https://doi.org/10.37349/emed.2020.00004
    Viewed:595
    Downloaded:9
    Cited:1
    Open Access
    Original Article
    Identifying factors associated with opioid cessation in a biracial sample using machine learning
    Aim: Racial disparities in opioid use disorder (OUD) management exist, however, and there is limited research on factors that influence opioid cessation in different population groups. Methods: ...
    Jiayi W. Cox ... Lindsay A. Farrer
    Published: February 29, 2020 Explor Med. 2020;1:27-41
    DOI: https://doi.org/10.37349/emed.2020.00003
    This article belongs to the special issue The Biological Basis of Substance Use Disorders
    Viewed:935
    Downloaded:33
    Cited:0
    Open Access
    Review
    Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions
    Retinopathy of prematurity (ROP) is a blinding morbidity of preterm infants, which represents a significant clinical problem, accounting for up to 40% of all childhood blindness. ROP dis...
    Lara Carroll, Leah A. Owen
    Published: February 29, 2020 Explor Med. 2020;1:4-26
    DOI: https://doi.org/10.37349/emed.2020.00002
    Viewed:736
    Downloaded:23
    Cited:0
    Open Access
    Editorial
    Welcome message from the Editor-in-Chief
    Lindsay A. Farrer
    Published: February 29, 2020 Explor Med. 2020;1:1-3
    DOI: https://doi.org/10.37349/emed.2020.00001
    Viewed:460
    Downloaded:18
    Cited:0
    • Article Type
      Editorial (1)
      Meta-Analysis (1)
      Original Article (3)
      Review (6)
      Year
      2020 (11)
      Volume
      Vol. 1 (2020)